M. Berk, Vincent Van den Eynde, Karthikeyan Ganapathy, C. Andrade, T. Birkenhäger, J. Bodkin, David Nutt, B. Barnett, Simeon Shalom Feinberg, Gordon Parker, E. Ruhe, M. Fornaro, Charles Redhead, Lila Godet, P. K. Gillman
{"title":"经典单胺氧化酶抑制剂治疗抑郁症的专家圆桌讨论-第二部分","authors":"M. Berk, Vincent Van den Eynde, Karthikeyan Ganapathy, C. Andrade, T. Birkenhäger, J. Bodkin, David Nutt, B. Barnett, Simeon Shalom Feinberg, Gordon Parker, E. Ruhe, M. Fornaro, Charles Redhead, Lila Godet, P. K. Gillman","doi":"10.3928/00485713-20230718-01","DOIUrl":null,"url":null,"abstract":"\n Experienced clinicians and academics from the International MAOI Expert Group comment on questions of interest concerning monoamine oxidase inhibitor (MAOI) pharmacotherapy for depression. These comments in this Part Two of the Expert Roundtable Discussion emphasize good pharmacological practice, starting with a low dose and progressing slowly and only changing one element at a time. Issues related to augmentation and drug combinations are also mentioned, including comments about the safety of ketamine. The special ability of MAOIs to improve dopamine function is highlighted, especially in relation to melancholic and psychotic depression.\n \n [\n Psychiatr Ann\n . 2023;53(8):364–369.]\n \n","PeriodicalId":20917,"journal":{"name":"Psychiatric Annals","volume":" ","pages":""},"PeriodicalIF":0.2000,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"An Expert Roundtable Discussion on the Use of Classic Monoamine Oxidase Inhibitors in the Treatment of Depression – Part Two\",\"authors\":\"M. Berk, Vincent Van den Eynde, Karthikeyan Ganapathy, C. Andrade, T. Birkenhäger, J. Bodkin, David Nutt, B. Barnett, Simeon Shalom Feinberg, Gordon Parker, E. Ruhe, M. Fornaro, Charles Redhead, Lila Godet, P. K. Gillman\",\"doi\":\"10.3928/00485713-20230718-01\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n Experienced clinicians and academics from the International MAOI Expert Group comment on questions of interest concerning monoamine oxidase inhibitor (MAOI) pharmacotherapy for depression. These comments in this Part Two of the Expert Roundtable Discussion emphasize good pharmacological practice, starting with a low dose and progressing slowly and only changing one element at a time. Issues related to augmentation and drug combinations are also mentioned, including comments about the safety of ketamine. The special ability of MAOIs to improve dopamine function is highlighted, especially in relation to melancholic and psychotic depression.\\n \\n [\\n Psychiatr Ann\\n . 2023;53(8):364–369.]\\n \\n\",\"PeriodicalId\":20917,\"journal\":{\"name\":\"Psychiatric Annals\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2023-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Psychiatric Annals\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3928/00485713-20230718-01\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychiatric Annals","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3928/00485713-20230718-01","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PSYCHIATRY","Score":null,"Total":0}
An Expert Roundtable Discussion on the Use of Classic Monoamine Oxidase Inhibitors in the Treatment of Depression – Part Two
Experienced clinicians and academics from the International MAOI Expert Group comment on questions of interest concerning monoamine oxidase inhibitor (MAOI) pharmacotherapy for depression. These comments in this Part Two of the Expert Roundtable Discussion emphasize good pharmacological practice, starting with a low dose and progressing slowly and only changing one element at a time. Issues related to augmentation and drug combinations are also mentioned, including comments about the safety of ketamine. The special ability of MAOIs to improve dopamine function is highlighted, especially in relation to melancholic and psychotic depression.
[
Psychiatr Ann
. 2023;53(8):364–369.]
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
